Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 187

1.

MYC is downregulated by a mitochondrial checkpoint mechanism.

Zhang X, Mofers A, Hydbring P, Olofsson MH, Guo J, Linder S, D'Arcy P.

Oncotarget. 2017 Oct 6;8(52):90225-90237. doi: 10.18632/oncotarget.21653. eCollection 2017 Oct 27.

2.

Proteasome-associated deubiquitinases and cancer.

Mofers A, Pellegrini P, Linder S, D'Arcy P.

Cancer Metastasis Rev. 2017 Dec;36(4):635-653. doi: 10.1007/s10555-017-9697-6. Review.

3.

Eradicating Quiescent Tumor Cells by Targeting Mitochondrial Bioenergetics.

Zhang X, De Milito A, Demiroglu-Zergeroglu A, Gullbo J, D'Arcy P, Linder S.

Trends Cancer. 2016 Nov;2(11):657-663. doi: 10.1016/j.trecan.2016.10.009. Epub 2016 Nov 11. Review.

PMID:
28741504
4.

Acute lymphoblastic leukemia cells are sensitive to disturbances in protein homeostasis induced by proteasome deubiquitinase inhibition.

Mazurkiewicz M, Hillert EK, Wang X, Pellegrini P, Olofsson MH, Selvaraju K, D'Arcy P, Linder S.

Oncotarget. 2017 Mar 28;8(13):21115-21127. doi: 10.18632/oncotarget.15501.

5.

Iron chelators target both proliferating and quiescent cancer cells.

Fryknäs M, Zhang X, Bremberg U, Senkowski W, Olofsson MH, Brandt P, Persson I, D'Arcy P, Gullbo J, Nygren P, Schughart LK, Linder S, Larsson R.

Sci Rep. 2016 Dec 7;6:38343. doi: 10.1038/srep38343.

6.

Corrigendum: The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells.

Wang X, Mazurkiewicz M, Hillert EK, Olofsson MH, Pierrou S, Hillertz P, Gullbo J, Selvaraju K, Paulus A, Akhtar S, Bossler F, Khan AC, Linder S, D'Arcy P.

Sci Rep. 2016 Jul 29;6:30667. doi: 10.1038/srep30667. No abstract available.

7.

The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells.

Wang X, Mazurkiewicz M, Hillert EK, Olofsson MH, Pierrou S, Hillertz P, Gullbo J, Selvaraju K, Paulus A, Akhtar S, Bossler F, Khan AC, Linder S, D'Arcy P.

Sci Rep. 2016 Jun 6;6:26979. doi: 10.1038/srep26979. Erratum in: Sci Rep. 2016 Jul 29;6:30667.

8.

Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors.

Shukla N, Somwar R, Smith RS, Ambati S, Munoz S, Merchant M, D'Arcy P, Wang X, Kobos R, Antczak C, Bhinder B, Shum D, Radu C, Yang G, Taylor BS, Ng CK, Weigelt B, Khodos I, de Stanchina E, Reis-Filho JS, Ouerfelli O, Linder S, Djaballah H, Ladanyi M.

Cancer Res. 2016 Aug 1;76(15):4525-34. doi: 10.1158/0008-5472.CAN-16-1040. Epub 2016 Jun 2.

9.

Targeting Mitochondrial Function to Treat Quiescent Tumor Cells in Solid Tumors.

Zhang X, de Milito A, Olofsson MH, Gullbo J, D'Arcy P, Linder S.

Int J Mol Sci. 2015 Nov 13;16(11):27313-26. doi: 10.3390/ijms161126020. Review.

10.

Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors?

Selvaraju K, Mazurkiewicz M, Wang X, Gullbo J, Linder S, D'Arcy P.

Drug Resist Updat. 2015 Jul-Aug;21-22:20-9. doi: 10.1016/j.drup.2015.06.001. Epub 2015 Jul 6. Review.

11.

Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15.

Wang X, D'Arcy P, Caulfield TR, Paulus A, Chitta K, Mohanty C, Gullbo J, Chanan-Khan A, Linder S.

Chem Biol Drug Des. 2015 Nov;86(5):1036-48. doi: 10.1111/cbdd.12571. Epub 2015 May 27.

12.

Deubiquitinase inhibition as a cancer therapeutic strategy.

D'Arcy P, Wang X, Linder S.

Pharmacol Ther. 2015 Mar;147:32-54. doi: 10.1016/j.pharmthera.2014.11.002. Epub 2014 Nov 6. Review.

13.

SIRT1 and SIRT2 inhibition impairs pediatric soft tissue sarcoma growth.

Ma L, Maruwge W, Strambi A, D'Arcy P, Pellegrini P, Kis L, de Milito A, Lain S, Brodin B.

Cell Death Dis. 2014 Oct 23;5:e1483. doi: 10.1038/cddis.2014.385.

14.

Regulation of TRAIL-receptor expression by the ubiquitin-proteasome system.

Sarhan D, D'Arcy P, Lundqvist A.

Int J Mol Sci. 2014 Oct 14;15(10):18557-73. doi: 10.3390/ijms151018557. Review.

15.

Elevation of proteasomal substrate levels sensitizes cells to apoptosis induced by inhibition of proteasomal deubiquitinases.

Sun C, Roboti P, Puumalainen MR, Fryknäs M, Wang X, D'Arcy P, Hult M, High S, Linder S, Swanton E.

PLoS One. 2014 Oct 6;9(10):e108839. doi: 10.1371/journal.pone.0108839. eCollection 2014.

16.

Molecular pathways: translational potential of deubiquitinases as drug targets.

D'Arcy P, Linder S.

Clin Cancer Res. 2014 Aug 1;20(15):3908-14. doi: 10.1158/1078-0432.CCR-14-0568. Review.

17.

Oncogenic functions of the cancer-testis antigen SSX on the proliferation, survival, and signaling pathways of cancer cells.

D'Arcy P, Maruwge W, Wolahan B, Ma L, Brodin B.

PLoS One. 2014 Apr 30;9(4):e95136. doi: 10.1371/journal.pone.0095136. eCollection 2014.

18.

The 19S Deubiquitinase inhibitor b-AP15 is enriched in cells and elicits rapid commitment to cell death.

Wang X, Stafford W, Mazurkiewicz M, Fryknäs M, Brjnic S, Zhang X, Gullbo J, Larsson R, Arnér ES, D'Arcy P, Linder S.

Mol Pharmacol. 2014 Jun;85(6):932-45. doi: 10.1124/mol.113.091322. Epub 2014 Apr 8.

19.

Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments.

Zhang X, Fryknäs M, Hernlund E, Fayad W, De Milito A, Olofsson MH, Gogvadze V, Dang L, Påhlman S, Schughart LA, Rickardson L, D'Arcy P, Gullbo J, Nygren P, Larsson R, Linder S.

Nat Commun. 2014;5:3295. doi: 10.1038/ncomms4295.

20.

A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.

Tian Z, D'Arcy P, Wang X, Ray A, Tai YT, Hu Y, Carrasco RD, Richardson P, Linder S, Chauhan D, Anderson KC.

Blood. 2014 Jan 30;123(5):706-16. doi: 10.1182/blood-2013-05-500033. Epub 2013 Dec 6.

21.

Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress.

Brnjic S, Mazurkiewicz M, Fryknäs M, Sun C, Zhang X, Larsson R, D'Arcy P, Linder S.

Antioxid Redox Signal. 2014 Dec 10;21(17):2271-85. doi: 10.1089/ars.2013.5322. Epub 2013 Oct 17.

22.

A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells.

Sarhan D, Wennerberg E, D'Arcy P, Gurajada D, Linder S, Lundqvist A.

Cancer Immunol Immunother. 2013 Aug;62(8):1359-68. doi: 10.1007/s00262-013-1439-1. Epub 2013 May 21.

PMID:
23689729
23.

Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling.

Wennerberg E, Sarhan D, Carlsten M, Kaminskyy VO, D'Arcy P, Zhivotovsky B, Childs R, Lundqvist A.

Int J Cancer. 2013 Oct 1;133(7):1643-52. doi: 10.1002/ijc.28163. Epub 2013 Apr 11.

24.

Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells.

Jarvius M, Fryknäs M, D'Arcy P, Sun C, Rickardson L, Gullbo J, Haglund C, Nygren P, Linder S, Larsson R.

Biochem Biophys Res Commun. 2013 Feb 8;431(2):117-23. doi: 10.1016/j.bbrc.2013.01.017. Epub 2013 Jan 11.

PMID:
23318177
25.

Gambogic acid is cytotoxic to cancer cells through inhibition of the ubiquitin-proteasome system.

Felth J, Lesiak-Mieczkowska K, D'Arcy P, Haglund C, Gullbo J, Larsson R, Linder S, Bohlin L, Fryknäs M, Rickardson L.

Invest New Drugs. 2013 Jun;31(3):587-98. doi: 10.1007/s10637-012-9902-y. Epub 2012 Nov 20.

PMID:
23179339
26.

Activated monocytes augment TRAIL-mediated cytotoxicity by human NK cells through release of IFN-γ.

Sarhan D, D'Arcy P, Wennerberg E, Lidén M, Hu J, Winqvist O, Rolny C, Lundqvist A.

Eur J Immunol. 2013 Jan;43(1):249-57. doi: 10.1002/eji.201242735. Epub 2012 Oct 26.

27.

Proteasome deubiquitinases as novel targets for cancer therapy.

D'Arcy P, Linder S.

Int J Biochem Cell Biol. 2012 Nov;44(11):1729-38. doi: 10.1016/j.biocel.2012.07.011. Epub 2012 Jul 20. Review.

PMID:
22819849
28.

The phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 is effective in inhibiting regrowth of tumour cells after cytotoxic therapy.

Hernlund E, Olofsson MH, Fayad W, Fryknäs M, Lesiak-Mieczkowska K, Zhang X, Brnjic S, Schmidt V, D'Arcy P, Sjöblom T, De Milito A, Larsson R, Linder S.

Eur J Cancer. 2012 Feb;48(3):396-406. doi: 10.1016/j.ejca.2011.11.013. Epub 2011 Dec 7.

PMID:
22154651
29.

Inhibition of proteasome deubiquitinating activity as a new cancer therapy.

D'Arcy P, Brnjic S, Olofsson MH, Fryknäs M, Lindsten K, De Cesare M, Perego P, Sadeghi B, Hassan M, Larsson R, Linder S.

Nat Med. 2011 Nov 6;17(12):1636-40. doi: 10.1038/nm.2536.

PMID:
22057347
30.

Identification of agents that induce apoptosis of multicellular tumour spheroids: enrichment for mitotic inhibitors with hydrophobic properties.

Fayad W, Rickardson L, Haglund C, Olofsson MH, D'Arcy P, Larsson R, Linder S, Fryknäs M.

Chem Biol Drug Des. 2011 Oct;78(4):547-57. doi: 10.1111/j.1747-0285.2011.01170.x. Epub 2011 Jul 29.

PMID:
21726416
31.

Multipotent mesenchymal stromal cells express FoxP3: a marker for the immunosuppressive capacity?

Sundin M, D'arcy P, Johansson CC, Barrett AJ, Lönnies H, Sundberg B, Nava S, Kiessling R, Mougiakakos D, Le Blanc K.

J Immunother. 2011 May;34(4):336-42. doi: 10.1097/CJI.0b013e318217007c.

32.

Focal adhesion kinase (FAK) activates and stabilizes IGF-1 receptor.

Andersson S, D'Arcy P, Larsson O, Sehat B.

Biochem Biophys Res Commun. 2009 Sep 11;387(1):36-41. doi: 10.1016/j.bbrc.2009.06.088. Epub 2009 Jun 21.

PMID:
19545541
33.

Reactivation of p53 function in synovial sarcoma cells by inhibition of p53-HDM2 interaction.

D'Arcy P, Ryan BA, Brodin B.

Cancer Lett. 2009 Mar 18;275(2):285-92. doi: 10.1016/j.canlet.2008.10.030. Epub 2008 Dec 9.

PMID:
19081178
34.

Differential roles of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth.

Törnkvist M, Natalishvili N, Xie Y, Girnita A, D'Arcy P, Brodin B, Axelson M, Girnita L.

Biochem Biophys Res Commun. 2008 Apr 11;368(3):793-800. doi: 10.1016/j.bbrc.2008.01.162. Epub 2008 Feb 11.

PMID:
18267106
35.

The oncoprotein SS18-SSX1 promotes p53 ubiquitination and degradation by enhancing HDM2 stability.

D'Arcy P, Maruwge W, Ryan BA, Brodin B.

Mol Cancer Res. 2008 Jan;6(1):127-38. doi: 10.1158/1541-7786.MCR-07-0176.

36.

Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling.

Maruwge W, D'Arcy P, Folin A, Brnjic S, Wejde J, Davis A, Erlandsson F, Bergh J, Brodin B.

Onco Targets Ther. 2008 Nov 1;1:67-78.

37.

[Reactions and interactions of drugs].

D'Arcy PF.

J Pharm Belg. 2000 Jul-Aug;55(4):111-2. French. No abstract available.

PMID:
10994303
38.

Are drug proprietary names necessary?

D'Arcy PF, Hadden DR.

Adverse Drug React Toxicol Rev. 2000 Jun;19(2):117-21. No abstract available.

PMID:
10967746
39.

[Reactions and interactions of drugs].

D'Arcy PF.

J Pharm Belg. 2000 Mar-Apr;55(2):49-52. French. No abstract available.

PMID:
10842926
40.

[Reactions and interactions of drugs].

D'Arcy PF.

J Pharm Belg. 1999 Sep-Oct;54(5):140-2. French. No abstract available.

PMID:
10596237
41.

Traditional Chinese medicines: safety hazards.

D'Arcy PF.

Adverse Drug React Toxicol Rev. 1999 Jun;18(2):53-7. No abstract available.

PMID:
10478284
42.

[Reactions and interactions of drugs].

D'Arcy PF.

J Pharm Belg. 1999 May-Jun;54(3):72-4. French. No abstract available.

PMID:
10431473
43.

[Reactions and interactions of drugs. Safety measures from Drug Safety Committee of the United Kingdom].

D'Arcy PF.

J Pharm Belg. 1999 Mar-Apr;54(2):44-7. Review. French. No abstract available.

PMID:
10380410
44.

[Reactions and interactions of drugs].

D'Arcy PF.

J Pharm Belg. 1998 Nov-Dec;53(6):352-3. French. No abstract available.

PMID:
9916376
45.

[Reactions and interactions of drugs].

D'Arcy PF.

J Pharm Belg. 1998 Sep-Oct;53(5):328-30. Review. French. No abstract available.

PMID:
9835676
46.

[Reactions and interactions of drugs].

D'Arcy PF.

J Pharm Belg. 1998 Jul-Aug;53(4):287-8. French. No abstract available.

PMID:
9766096
47.

[Reactions and interactions of drugs].

D'arcy PF.

J Pharm Belg. 1997 Sep-Oct;52(5):209-10. French. No abstract available.

PMID:
9432529
48.

ICH4: a report and background.

D'Arcy PF.

Adverse Drug React Toxicol Rev. 1997 Aug;16(3):199-206. No abstract available.

PMID:
9512764
49.

[Reactions and interactions of drugs].

D'Arcy PF.

J Pharm Belg. 1997 Jul-Aug;52(4):171-2. French. No abstract available.

PMID:
9379339
50.

Adverse drug reactions in hospital and in the community.

D'Arcy PF.

Adverse Drug React Toxicol Rev. 1997 Jun;16(2):95-101. Review. No abstract available.

PMID:
9359931

Supplemental Content

Loading ...
Support Center